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Abstract
Previous studies have characterized the prevalence and duration of serum IgG antibodies to human papillomavirus type 16 (HPV 16) in
a well-studied cohort of college women, using viruslike particle- (VLP) based ELISAs. In this study IgA antibodies in cervical secretions
and sera were examined using a newly developed capsomer-based ELISA and the patterns observed for serum IgG, serum IgA, and cervical
IgA antibodies were compared. The median time to antibody detection from the first detection of HPV 16 DNA was 10.5 months for IgA
in cervical secretions and 19.1 months for serum IgA. Serum IgA antibody conversion was observed less frequently and occurred later than
IgA conversion in cervical secretions (P  0.011) or serum IgG conversion (P  0.051). The median time to antibody reversion, following
seroconversion, was 12.0 months for IgA in cervical secretions and 13.6 months for serum IgA, whereas approximately 20% of women with
serum IgG antibodies reverted within 36 months. Thus, the duration of IgA in cervical secretions and sera was shorter than the duration of
serum IgG (P  0.007 and 0.001).
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Several human papillomavirus (HPV) types, including
HPV 16 and HPV 18, are causative agents of cervical
cancer, which is one of the leading causes of death due to
cancer among women worldwide (Working Group on the
Evaluation of Carcinogenic Risk to Humans, 1995; Viz-
caino et al., 2000). Animal studies have demonstrated that
papillomavirus vaccines using viruslike particles (VLPs)
composed of the major capsid protein (L1) or L1 and L2
provide protection from primary infection (Breitburd et al.,
1995; Suzich et al., 1995; Kimbauer et al., 1996). In the
canine and rabbit models, protection was shown to be me-
diated by neutralizing antibodies (Breitburd et al., 1995;
Suzich et al., 1995). Vaccine studies conducted in humans
have shown that VLP immunization induces high-titer neu-
tralizing antibodies (Harro et al., 2001; Brown et al., 2001).
The effectiveness and longevity of protection provided by
these vaccines is being evaluated. Some insight into the
potential utility of these vaccines may be gained by an
understanding of the natural history of the antibody re-
sponse following naturally acquired infections.
Previous studies by this laboratory have focused on the
natural history of serum IgG responses to HPV types 16, 18,
and 6 (Carter et al., 1996, 2000). IgA is the second most
abundant isotype in serum and plays an important role for
protection against pathologic agents at mucosal sites
(Mestecky and Fultz, 1999). A number of cross-sectional
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studies have demonstrated that IgA responses specific for
HPV VLPs correlate with IgG responses or with the detec-
tion of HPV DNA of that type (Heim et al., 1995; Wang et
al., 1996; Sasagawa et al., 1998; van Doomum et al., 1998;
Petter et al., 2000). Longitudinal studies are required to
characterize the natural history of immune responses. Only
a few such studies have been conducted (Bontkes et al.,
1999; Hagensee et al., 2000). Thus, the time between the
acquisition of HPV infections and the development of spe-
cific IgA antibodies and the duration of these responses
remains largely undefined.
Most studies of HPV-specific antibodies have employed
VLPs produced in insect cells; however, highly immuno-
genic and genotype-restricted HPV capsid-neutralizing an-
tigenic domains were shown to be contained entirely within
capsomers (Li et al., 1997; Rose et al., 1998). The HPV
VLP is composed of 72 capsomers, each of which is a
pentamer of 5 L1 proteins (Chen et al., 2000). Assembly of
capsids from capsomers was shown to be promoted by
intercapsomeric disulfide bonds between certain cysteine
residues (Sapp et al., 1995; Li et al., 1998; Modis et al.,
2002) and mutation of particular cysteines in the C-terminal
region of HPV 33 L1 was shown to assemble only into
capsomers (Sapp et al., 1998). Comparison of bacterially
produced HPV 11 VLPs with HPV 11 VLPs produced in
insect cells found them to be immunologically indistin-
guishable (Li et al., 1997). These results suggested that HPV
capsomers can be generated in a bacterial expression system
and that capsomers may serve as effective and economical
antigens in seroepidemiologic studies of HPV.
This study was designed to characterize the natural
course of IgA responses in cervical secretions and sera
against HPV 16 capsid proteins in comparison with IgG
responses in sera. The women in this study had few previous
sex partners and were HPV 16 DNA and serum antibody
negative upon entry into the study. It is, therefore, likely that
the antibody responses characterized here resulted from an
initial exposure to the virus. The detection of HPV DNA in
women who had entered the study HPV DNA and serum
negative was considered to be evidence of incident infec-
tion. These studies employed an ELISA using bacterially
expressed HPV 16 capsomers as antigen in order to develop
a lower cost, and potentially more sensitive, antibody de-
tection assay.
Results
Expression and purification of 16L1 capsomers
To produce HPV 16 L1 capsomers in bacteria, mutations
were made in the HPV 16 L1 sequence such that cysteines
175 and 427 were converted to serines. HPV 16 L1 protein
expression, under control of the Lac promoter, was induced
and the cells harvested as described under Materials and
Methods. Purification consisted of centrifugation, ammo-
nium sulfate precipitation, and two rounds of ion-exchange
chromatography as described under Materials and Methods
and as shown in Fig. 1. L1 was eluted from the column in
the final two washes (lanes 4 and 5). Only the L1 in the final
wash (lane 5) was used for antibody testing.
Reactivity of HPV 16 capsomers in capture assay and
direct assay
Our previous serological studies have used a capture
ELISA format in which monoclonal antibodies that recog-
nize conformational epitopes on the VLP are used to tether
the VLPs to the plate (Carter et al., 2000). However, several
other investigators bind VLPs directly to the plate (Wang et
al., 1996; Wideroff et al., 1995). We investigated how the
capsomers would perform in both capture and direct
ELISAs. The ELISA values of 48 serum samples from HPV
16 DNA-positive women were measured in a direct cap-
somer assay for IgG and compared with capture VLP IgG
ELISA values (Fig. 2). The sera were selected from a cohort
of women who were monitored for the presence of HPV
DNA. All of the sera shown here were from women who
tested HPV 16 DNA positive prior to or at the time sera
were drawn. The ELISA values for the direct capsomer
assay correlated well with those in the capture-VLP assay.
The R values (Pearson’s coefficient of correlation) and P
values were R  0.846 and P  0.0001. Capsomers were
also used in a capture assay and a somewhat better corre-
lation with the capture-VLP ELISA values (R 0.935) was
observed. However, from this and other experiments (not
Fig. 1. Purification of 16L1 capsomers. Fractions were saved during the
purification of 16L1 capsomers from bacteria and run a 10% SDS–PAGE.
The top panel shows the Coomassie blue-stained gel. The lanes are marked
as follows: (M) molecular weight size markers, (1) crude lysate applied to
the column, (2) flow-through from the P11 column, (3) elution using 250
mM NaCl buffer, (4) elution using 500 mM NaCl buffer, (5) elution using
1 M NaCl buffer, HPV 16 L1 from vaccinia virus. 16L1 was detected using
Camvir-1 in the immunoblot shown in the lower panel.
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shown), it was determined that the capture capsomer ELISA
was less sensitive than the direct capsomer ELISA. There-
fore, capsomer assays for IgA detection in cervical secre-
tions and sera were performed using direct assays.
Correlation of DNA and antibody status
Women with incident HPV 16 infections, that is, women
who entered the study HPV 16 DNA negative and HPV 16
seronegative and subsequently had HPV 16 DNA detected
at one or more visits during follow-up (n  57), were the
focus of this study. In order to be included for analysis,
serum or cervical secretions had to be collected within 4
months of the detection of HPV 16 DNA. This resulted in
24 women for the analysis of cervical secretions, 44 women
for the analysis of serum IgA, and 52 women for serum IgG.
The presence of IgA in cervical secretions and sera was
tested by capsomer ELISA and these results were compared
with previous results for serum IgG detection using a VLP-
capture ELISA (Carter et al., 1996, 2000). Antibody status
was compared with the presence of DNA in these women
(Table 1). HPV 16 DNA status was divided into three
categories; visits prior to the first HPV 16 DNA detection,
HPV 16 DNA positive visits, and visits that were HPV 16
DNA negative from subjects that had previously tested
positive. Antibodies were detected more frequently among
samples collected at the time of DNA positivity than prior to
the detection of HPV 16 DNA for all antibody types.
IgA in cervical secretions was detected in 7 of 66
(10.6%) samples taken prior to HPV 16 DNA detection
compared with 23 of 67 (34.3%) samples collected at HPV
16 DNA positive visits. Similarly, serum IgA was detected
in only 3 of 172 (1.7%) samples collected prior to the first
detection of HPV 16 DNA but in 32 of 135 (23.7%) samples
collected coincident with HPV DNA detection; serum IgG
was detected in only 8 of 218 (3.7%) samples prior to HPV
16 DNA detection but in 53 of 149 (35.6%) samples col-
lected at the time of HPV 16 DNA positivity.
IgA was detected less frequently in samples collected
after HPV 16 DNA was no longer detected compared with
samples collected at DNA positive visits, but this pattern
was not seen for serum IgG (Table 1). Cervical IgA was
detected in 9 of 52 (17.3%) samples and serum IgA was
detected in 18 of 115 (15.7%) sera; however, serum IgG
was detected in 62 of 120 (51.7%) sera from visits of
previously HPV 16 DNA positive women.
The specificity of the IgA assays for HPV 16 was as-
sessed by comparing the antibody status between women
who had other types of HPV DNA detected by PCR (other
than HPV 16) with women who had had no HPV detected
prior to antibody testing. For IgA in sera, there were 3
seropositive women among the 102 (2.9%) specimens (from
38 women) who had tested HPV DNA negative. There were
no (0.0%) seropositives among the 70 samples from 34
women in whom other types of HPV DNA had been de-
tected (16 women acquired other types of HPV DNA during
the study and thus contributed sera to both categories).
Among the cervical specimens there were 4 antibody pos-
itives among the 31 (12.9%) samples from 12 women who
were HPV DNA negative and 3 antibody positives detected
among the 35 (8.6%) samples from 13 women in whom
other HPV DNA types were detected. Three women con-
tributed specimens to both categories.
Time to first antibody detection
The median time to first antibody detection was 10.5
months for IgA in cervical secretions, 19.1 months for
serum IgA, and 10.8 months for serum IgG (Fig. 3). The
cumulative rates of antibody conversion at 18 months for
IgA in cervical secretions, serum IgA, and serum IgG were
87.3, 47.7, and 64.7% respectively. Serum IgA conversion
was slower than conversion for cervical IgA (log rank, P 
0.01, Cox) and serum IgG (P  0.05, Cox). There was no
significant difference in the conversion rate for IgA in
cervical secretions vs the conversion rate for serum IgG (P
Fig. 2. Reactivity of HPV 16 capsomer with serum samples taken from
HPV 16 DNA-positive women was compared with those of an HPV 16
VLP capture ELISA. Figure 1 shows the correlation of ELISA values
between a direct capsomer IgG assay and a capture VLP IgG assay.
Table 1






Negative 59 44 43
Positive 7 23 9
Total 66 67 52
Serum IgA
Negative 169 103 97
Positive 3 32 18
Total 172 135 115
Serum IgG
Negative 210 95 57
Positive 8 53 62
Total 218 148 119
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 0.22, Cox). Figure 3 shows the results of analysis, in-
cluding 477 serum samples from 52 women and 124 cervi-
cal secretions from 24 women (total of 55 women). Con-
cerning the analysis comparing serum IgG with IgA, similar
results were obtained when the analysis was restricted to the
337 samples from 44 women for whom there was data for
serum tests for both IgA and IgG (not shown). When the
analysis was restricted to 20 women for whom there were
cervical IgA as well as serum IgA and serum IgG results,
serum IgA conversion was still significantly slower than
cervical IgA (P  0.04).
Persistence of antibodies
For the analysis of antibody persistence, the same set of
women with incident HPV 16 infection as described above
was used with the additional criterion being that they must
have converted from an antibody negative to an antibody-
positive status. Fourteen women were used for the analysis
of IgA antibody persistence in cervical secretions, 25
women for serum IgA, and 34 women for serum IgG (42
different women in total). Figure 4 shows the rates of
reversion to a negative antibody test among women who
had at least one positive antibody test. The median time to
antibody reversion was 12.0 months for IgA in cervical
secretions and 13.6 months for serum IgA. More than 50%
of women who developed serum IgG remained seropositive
throughout follow-up. Serum IgG was more likely to persist
than IgA in cervical secretions and sera (P  0.007 and
0.001, Cox). There was not a significant difference between
IgA in cervical secretions and serum IgA antibody persis-
tence (P  0.73, Cox).
Figure 4 shows the results of analysis, including all
women eligible for the analysis (42 women in total). When
analysis was restricted to the 21 women who developed
both serum IgA and serum IgG, IgG was more likely to
persist than serum IgA (P  0.007). Only 4 women pro-
vided persistence information for all three antibody types.
DNA duration and antibody conversion
Production of antibodies and the DNA-positive periods
were related (Fig. 5). Women were divided into two cate-
gories (i.e., women who were DNA positive at one visit
only and women with multiple HPV 16 DNA-positive vis-
its). The rate of antibody conversion was analyzed by
Kaplan–Meier survival methods. The percentage of anti-
body conversion among women with multiple DNA-posi-
tive visits and women HPV 16 DNA positive only once was,
respectively, 72.5 and 0% at 1 year for IgA in cervical
secretions, 59.9 and 25% at 2 years for serum IgA, and 75.2
and 20% at 2 years for serum IgG. Though differences
between the serum IgA curves did not reach statistical
significance (P  0.299, log rank test), the differences
between cervical IgA curves and serum IgG curves were
statistically significant (P  0.030 and 0.040, log rank test).
The influence of DNA duration on antibody conversion was
further analyzed by subdividing the women with multiple
DNA-positive results into groups based upon the duration of
DNA positivity (e.g., less and not less than 12 months or
less and not less than 6 months of DNA duration). These
analyses revealed no differences between the groups for the
production of three antibodies (data not shown).
Discussion
In the present study we examined IgA responses against
HPV 16 L1 in cervical secretions and sera and compared
those responses with serum IgG responses among women
who acquired what were likely to be primary HPV 16
infections. The most interesting finding was the obvious
Fig. 3. Time to first antibody detection was analyzed using Kaplan–Meier
analysis. Solid black, solid dark gray, and solid light gray lines show the
positive rates of IgA in cervical secretions, IgA and IgG in serum samples,
respectively.
Fig. 4. Durations of antibodies were analyzed using Kaplan–Meier analy-
sis. Solid black, solid dark gray, and solid light gray lines show the positive
rates of IgA in cervical secretions and IgA and IgG in serum samples,
respectively.
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difference between the persistence of the IgG responses
over time and the transient nature of the IgA responses. IgA
seroconversion appeared to be delayed relative to the IgG
response and, like the IgG response, usually occurred many
months after the first detection of HPV DNA.
In line with previous observations using HPV 16 VLPs
as antigen (Wang et al., 1996; Sasagawa et al., 1998; Bont-
kes et al., 1999), the presence of IgA in cervical secretions,
IgG in sera, and IgA in sera were associated with the
presence of HPV 16 DNA in genital mucosa at the time of
collection. IgA in cervical secretions and serum anti-VLP
antibodies were detected at much higher frequencies in
samples collected coincident with HPV 16 DNA detection
compared with samples collected before HPV DNA detec-
tion (Table 1).
Concerning the time to antibody detection and duration
of serum IgG, we and others reported that IgG seroconver-
sion against HPV 16 generally occurs within 6 (Wikstrom et
al., 1995) to 12 (Carter et al., 2000) months after HPV 16
infection and that IgG response remains high over a long
period of time (van Doornum et al., 1998; Af Geijersstam et
al., 1998; Carter et al., 2000). Limited information is avail-
able on the natural history of IgA in cervical secretions and
IgA in sera and it is not entirely consistent. Wang et al.
(1996) reported that a substantial proportion of women
positive for IgA in cervical mucus remained positive at their
subsequent visits, although exact intervals between visits
were not shown. Sasagawa et al. (1998) demonstrated an
early appearance and longer persistence of serum IgA com-
pared to serum IgG, and Elfgren et al. (1996) reported that
after conization for cervical intraepithelial neoplasia, serum
IgA was more stable than serum IgG and cervical mucosal
IgA, though this observation was not based on data from a
natural history study.
To better characterize the temporal patterns of antibody
conversion and duration, we analyzed time to antibody
conversion and reversion during longitudinal follow-up.
Different patterns of production and reversion for IgA in
cervical secretions and IgG and IgA in sera were found
(Figs. 3 and 4). After HPV 16 DNA infection, 64.7% of
women developed serum IgG antibodies by 18 months (me-
dian time to detection; 10.8 M). Duration of antibodies were
long (only 1 reverted by year 3). IgA in cervical secretions
was detected in 87.3% of women within 18 months of the
first detection of HPV 16 DNA and occurred coincident
with serum IgG (median time to detection; 10.5 M). Dura-
tion of IgA antibodies was short (50% reverted by month
12). IgA in sera developed more slowly than IgA in the
cervical mucosa or serum IgG (median time to detection;
19.1 M) and a lower percentage of women developed serum
IgA (47.7% within 18 months). Similar to IgA in cervical
secretions, the duration of serum IgA antibodies was short
(50% seroreverted within 14 months). Several reports have
suggested that anti-HPV antibody responses persist (Wang
et al., 1996; Elfgren et al., 1996; Sasagawa et al., 1998);
however, Wang et al. (2000) reported that serum IgA was
associated with recent sexual activity and suggested that this
meant serum IgA did not persist. Our results are consistent
with Wang et al. and reminiscent of the pattern seen for
Chlamydia trachomatis serum IgA antibody responses (Os-
borne et al., 1989) where these responses were a marker for
active infections. It must be noted that there were too few
women (4) for whom we had samples who converted to all
three antibodies (serum IgA and IgG and cervical IgA) to do
a comparison.
HPV 16 DNA persistence for longer than one visit has
been shown to be associated with IgG seropositivity
(Wideroff et al., 1995; de Gruijl et al., 1997; Carter et al.,
2000) and IgA seropositivity (Sasagawa et al., 1998; Bont-
kes et al., 1999) for HPV 16 VLPs. In agreement with these
observations, our data showed that the production of serum
IgA occurred less frequently among women with only one
DNA positive visit. A correlation was also observed be-
tween HPV 16-specific IgA responses in cervical secretions
and the number of HPV 16 DNA-positive visits. In addition,
our data revealed higher rates of both IgA and IgG sero-
Fig. 5. Association between persistence of HPV 16 DNA detection and
antibody detection. Survival curves compare rates of antibody detection
between women who were HPV 16 DNA positive only once (solid black
lines) and women having several HPV 16 DNA-positive visits (solid dark
gray lines) for IgA in cervical secretions (A), IgA in sera (B), and IgG in
sera (C).
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conversion among women with versus those without re-
peated detection of HPV 16 DNA in genital samples. Thus,
the duration of HPV 16 DNA in genital mucosa seems to be
an important factor for the production of IgA in cervical
secretions and IgG and IgA in sera.
The experiments presented here employed a new ELISA
system for the detection of IgA antibodies, using bacterially
expressed and purified HPV 16 capsomers as antigens in-
stead of HPV 16 VLPs expressed in eukaryotic cells using
vaccinia virus or baculovirus vectors (Carter et al., 1996).
The new assay was developed as part of a continuing search
for improved methods for the detection of antibodies to
HPVs. To evaluate the new ELISA, this test was compared
to a VLP capture assay using selected human sera (Fig. 2).
The results from direct capsomer IgG assays correlated well
with those from the capture VLP IgG assay. No samples
were identified that reacted only with VLPs. These results
suggested that bacterially expressed capsomers possessed
conformational epitopes that were similar to those on whole
VLPs and that only very weak or no epitopes exist at
intercapsomeric regions of VLPs. Therefore, capsomers
seemed to serve as useful antigens for detection of anti-HPV
16 L1 antibodies. In a previous study (Hagensee et al.,
2000), a luminescence immunoassay was used to improve
sensitivity of the detection of IgG and IgA antibodies in
cervical secretions. It was not possible to directly compare
the results from the capsomer assay with Hagensee’s results
because the cervical samples previously tested were no
longer available. However, the capsomer IgA assay ap-
peared to have a similar or higher sensitivity than the cap-
ture-VLP luminescent IgA assay because the proportion of
seroconversions observed in women with incident HPV 16
DNA was higher with the capsomer assay than the lumi-
nescent assay (data not shown).
If the use of capsomers was less sensitive for the detec-
tion of HPV 16 IgA than a VLP based assay it would be
anticipated that antibodies would be detected less frequently
among HPV 16 DNA-positive women. It was found here
that the proportion of women developing antibodies to IgA,
as detected by the capsomer ELISA, was not significantly
different than the proportion of women seroconverting for
IgG, as detected by the capture capsid ELISA (Fig. 3),
suggesting that the assays had similar sensitivity.
The specificity of the IgA capsomer ELISA was assessed
by examination of the results from women in whom HPV 16
DNA had not been detected at previous or current visits (see
Table 1). For cervical specimen 10.6% were IgA antibody
positive, whereas only 1.7% of sera were IgA antibody
positive. In neither case was antibody positivity associated
with the detection of other HPV types in these women (not
shown). The results from sera indicated that the use of
capsomers produced a highly specific assay. The assay for
antibodies in cervical specimen was less specific perhaps
due to the use of more concentrated samples.
In conclusion, we developed a new ELISA using HPV 16
capsomers to detect IgA directed against HPV 16 L1 pro-
teins. The ELISA values for the direct capsomer assay
correlated well with those in the capture-VLP assay. Com-
pared with IgG serum antibody responses, IgA antibody




The University of Washington Human Subjects Division
approved all protocols and consent forms. The study popu-
lation was a subset of the 603 female university students
enrolled in a study of the natural history of HPV infection
described previously (Hagensee et al., 2000; Carter et al.,
2000). Clinic visits were scheduled at 4-month intervals. At
each clinic visit, cervical and vulvovaginal swabs for the
detection of HPV DNA, as well as blood and cervical
secretions (from June 1994) for the detection of HPV anti-
bodies, were collected.
Detection of HPV DNA
The presence of HPV DNA was determined by PCR
using the MY09 and MY11 consensus primers as described
previously (Carter et al., 1996). The PCR products were
probed with a biotin-labeled generic HPV probe and type-
specific oligonucleotide probes that included a probe for
HPV 16. The samples whose PCR products reacted with
both generic HPV probe and type-specific HPV 16 probe
were determined as HPV 16 positive.
Collection and preparation of cervical secretions
Cervical secretions were collected using two tear flow
test strips (Sno-Strips, Abita Springs, LA, USA) placed on
the cervical os until they were saturated to the shoulder.
After absorption of cervical secretions, strips were removed
and placed into a vial containing 500 l of sterile phos-
phate-buffered saline (PBS with 0.01% sodium azide), and
the samples were kept frozen at 20°C until use. Before
use, samples were thawed, mixed with 125 l of 5 RIPA
buffer [750 mM NaCl, 5.0% Nonidet P-40, 2.5% deoxycolic
acid, 0.5% sodium dodecyl sulfate, and 250 mM Tris–HCl
(pH 8.0)], and incubated for 1 h at room temperature. Then,
the strips were removed by centrifugal filtration (20,000g
for 15 min.) using a 0.45-m centrifugal filter (Ultrafree-
MC, Millipore, Bedford, MA, USA). In a previous study
using cervical secretions (Hagensee et al., 2000), the total
amount of protein, the total amount of IgG and IgA, and the
presence of blood were measured. None of these variables
were found to be useful in the final analysis and the practice
was not continued in these studies.
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Preparation of HPV 16 capsomers
Primers were designed to make 16 L1 proteins with
double Cys to Ser mutations at positions 175 and 428. The
primers also contained restriction endonuclease sites for
stepwise cloning. [5-TGACTGAAGCTTGGTCTCACAT-
GTCTCTTTGG (first sense), 5-CAGTCATCTAGAGTC-
GACGGGGATCCTTTG (first antisense), 5-TGACT-
GTCTAGAGTCGACCAATGTTGCAGTAAATCC (second
sense), 5-CAGTCATCTAGAGCTAGCAATTGCCT-
GGGATG (second antisense), 5-TGACTGTCTA-
GAGCTAGCCAAAAACATACACC (third sense) and
5-CAGTCATCTAGACTCGAGTTACAGCTTACG (third
antisense)]. The 5 fragment of HPV 16 L1 was generated
by PCR using a high-fidelity polymerase (Deep Vent, New
England Biolabs, Mississauga, Ontario, Canada). The poly-
merase chain reaction (PCR) product was digested with
restriction enzymes and cloned into pBS- (Stratagene, La
Jolla, CA, USA). The other two fragments were generated
by PCR and cloned into the same plasmid in a stepwise
fashion. The final product was sequenced to verify the
changes. The mutated L1 coding region was subcloned into
pET19b (Novagen, Madison, WI, USA)(pET19b/HPV
16L1).
pET19b/HPV 16L1 was introduced into host bacteria
(DE3). Bacteria were grown in LB medium with 200 g/ml
of ampicillin, and then L1 proteins were expressed over-
night at 30°C after induction with 1 mM of isopropyl--D-
thiogalactopyranoside (IPTG). L1 proteins were purified
through centrifugal fractionation and ion-exchange column
procedures generally as previously described (Li et al.,
1997) except for omitting the Polymin P step. Bacteria from
2 liters of culture were suspended in 200 ml of buffer A
[0.25 M NaCl, 50 mM Tris–HCl (pH 7.9), 5% glycerol, 2
mM EDTA, 15 mM 2-mercaptoethanol (2ME)] and incu-
bated with 200 g/ml of lysozyme at 4°C for 20 min. Then
Triton  (final concentration of 0.1%) and 4 tablets of
Complete (Roche, Indianapolis, IN, USA) were added. The
mixture was sonicated with a Branson Sonifier (Model No.
250, VWR Scientific, Willard, OH, USA) for 3 times of
40-s. bursts at 1-min intervals. The sonicated suspension
was subjected to 20 rounds of homogenization with Kontes
Dounce Tissue Grinder (VWR Scientific). The homogenate
was centrifuged at 12,000g for 20 min and the pellet ex-
tracted with 100 ml of buffer B [1 M NaCl, 10 mM Tris–
HCl (pH 7.9), 5% glycerol, 2 mM EDTA, 15 mM 2ME]
with homogenization. The suspension was centrifuged at
10,000g for 15 min. Supernatants were combined and pre-
cipitated with 35% saturation of ammonium sulfate. This
precipitate was resuspended in 20 ml of buffer C1 [100 mM
NaCl, 10 mM Tris–HCl (pH 7.2), 5% glycerol, 2 mM
EDTA, 15 mM 2ME] and dialyzed against the same buffer.
Insoluble material was removed by centrifugation at
10,000g for 20 min. Supernatant was loaded on DE-52
(Whatman, Clifton, NJ, USA) anion exchange cellulose
column with buffer C1. The flow-through was applied to a
P11 (Whatman) cation-exchange cellulose column. The col-
umn was washed with buffer C2 [250 mM NaCl, 10 mM
Tris–HCl (pH 7.2), 5% glycerol, 2 mM EDTA, 15 mM
2ME] and buffer C3 [500 mM NaCl, 10 mM Tris–HCl (pH
7.2), 5% glycerol, 2 mM EDTA, 15 mM 2ME]. Protein (L1)
was eluted with buffer C4 [1 M NaCl, 10 mM Tris–HCl (pH
7.2), 5% glycerol, 2 mM EDTA, 15 mM 2ME].
Detection of antibodies against HPV 16 L1 proteins
Detection of serum IgG antibodies was performed using
HPV 16 VLPs as previously described (Carter et al., 1996).
To detect IgA antibodies in sera and cervical secretions,
purified HPV 16 capsomers were used as antigens. Wells of
microtiter plates (Immulon 2, Dynatech Laboratories Inc.,
Chantilly, VA, USA) were coated with or without 200 ng of
HPV 16 capsomers in 50 l of PBS. The plates were
incubated at 4°C overnight, washed 3 times with PBS,
blocked with 100 l/well of blocker (5% goat serum and
0.05% Tween 20 in PBS), and incubated at room tempera-
ture for 1 h. Fifty microliters per well of sera (1:100 dilu-
tion) or cervical secretion (1:10 dilution of sample after
extraction from strip as described above) in blocker was
added and incubated at 37°C for 1 h. Plates were washed 3
times with PBS and incubated with 1/1000 dilution of rabbit
antihuman IgA (Sigma, St. Louis, MO USA) at 37°C for
1 h. After washing 3 times with PBS plates were incubated
with 1/1000 dilution of goat antirabbit IgG conjugated with
alkaline phosphatase (ALP) (Roche No. 0605415) at 37°C
for 1 h. Plates were washed as before and 100 l of Sigma
104 phosphatase substrate (Sigma) was added [4.33 mg/ml
in 0.1 M NaHCO3 and 0.01 M MgCl2 (pH 9.5)], to each
well, plates were incubated at room temperature for 30 min.
The optical densities were read on an automated plate reader
(Elx808, BIO-TEK Instruments Inc., Winooski, VT, USA).
Samples were tested in triplicate with and without capso-
mers. The ELISA values were calculated as the natural log
of the median OD measurements with capsomers minus the
natural log of the median OD measurements without cap-
somers as previously described (Carter et al., 1996). The
cutoff points were calculated as the mean  2 SD of the
values of samples from 32 study participants who reported
no sex partners and who were negative for HPV DNA. To
remove the reactivity with bacterial proteins, all samples
were preabsorbed with 1% (serum samples) or 0.1% (cer-
vical secretions) acetone powder of DE3 bacterial proteins
at 4°C for 1 h. The cross-reactivity of human IgG with
rabbit antihuman IgA or goat antirabbit IgG was examined.
Human IgG showed no reaction and did not affect the
reaction of human IgA (data not shown).
Statistical analysis
Linear regression analyses were performed to compare
the reactivity of HPV 16 capsomer and VLP. The associa-
tion between antibody status and DNA status was analyzed
219T. Onda et al. / Virology 312 (2003) 213–221
with Fisher’s exact test. For the analysis of time to first
antibody detection and duration of antibodies, the Kaplan–
Meier product limit method was used (Kaplan and Meier,
1958). Analysis of the differences between the curves was
performed using the logrank test or Cox model with adjust-
ment for repeated observations within individual (Lin,
1994).
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